CA-GLOBALLOGIC
28.9.2021 02:02:16 CEST | Business Wire | Press release
Hitachi, Ltd. (TSE: 6501, “Hitachi”) and GlobalLogic*1 , a Hitachi Group Company, today announced the launch of a collaborative hub to promote digital transformation (DX) services in the Japanese market. Based in the Lumada Innovation Hub Tokyo*2 , a co-creation base for Hitachi, this collaboration hub combines capabilities of GlobalLogic and Lumada. Delivering on the joint integration strategy, this partnership aims to jump-start GlobalLogic’s entry into Japan, and will accelerate business development for design-led Digital Engineering services of GlobalLogic, establishing a system to support customers in Japan starting from fiscal 2022.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210927005848/en/
"The market demand for DX continues to grow at a fast pace, as global brands increasingly leverage digital technologies to create new revenue streams and better engage customers,” said Nitesh Banga, Chief Operating Officer, GlobalLogic. “GlobalLogic and Hitachi are well positioned to address this need, and the launch of the collaboration Hub will be a great first step in bringing expanded DX capability to the Japan market."
Recently acquired by Hitachi in July 2021 and operating as a Hitachi Group Company, GlobalLogic is a leader in Digital Engineering services, with capabilities that span Strategy, Experience Design, and Chip-to-Cloud software engineering. GlobalLogic not only provides upstream services such as product ideation, but also implements that vision into actual products, platforms, and experiences.
Hitachi has the expertise and experience in DX that has been cultivated in the Lumada business, including design thinking and data science, and is working with customers and partners to create new value by combining wisdom and ideas.
As the first project to leverage the strengths of both companies, Hitachi and GlobalLogic have begun work to accelerate the transformation of Hitachi's Storage business into a cloud-based "as-a-Service" business model. This initiative will enable Hitachi and GlobalLogic to create and customize joint service offerings for the Japanese market.
About the Collaboration Between Hitachi and GlobalLogic
Lumada Innovation Hub Tokyo and GlobalLogic's design studios and engineering centers around the globe are connected online, and workshops are being conducted for collaborative projects, leveraging GlobalLogic's extensive DX implementation experience, experience design, and capabilities in Chip-to-Cloud software engineering. Hitachi and GlobalLogic will implement projects that accelerate DX for customers in Japan.
Design thinkers*3 from Lumada Innovation Hub Tokyo, with expertise in the industries and businesses of the Japanese market, will work with Hitachi business stakeholders and GlobalLogic's designers and solution architects to identify transformational goals. GlobalLogic's rapid problem-solving approach will be applied to develop DX strategies and quickly create business model prototypes.
The first workshop was held for Hitachi's storage business, where Hitachi and GlobalLogic worked on architectures to enhance cloud readiness. By leveraging GlobalLogic's digital engineering services, Hitachi will strengthen and accelerate its "as-a-Service" model for its storage business. Hitachi and GlobalLogic will apply the outcomes of this workshop to Hitachi's other product businesses to accelerate DX for its customers.
Future Opportunities
Based on the new, co-created business process established through this project, Hitachi will test its applicability against a variety of digital transformation projects and plans to launch the service to Japanese customers in fiscal 2022.
In the future, GlobalLogic's more than 22,000 design and software engineering professionals around the world and Hitachi's 35,000 digital professionals will work together through the Lumada Innovation Hub Tokyo to promote Social Innovation Businesses that leverage digital technology to solve problems faced by customers and society globally, including the Japanese market.
Collaboration Introduction at Hitachi Social Innovation Forum 2021 JAPAN
You can learn more about this collaboration at the “Hitachi Social Innovation Forum 2021 JAPAN” from October 11th (Monday) to 15th (Friday), 2021. The project will be showcased in the following sessions:
- October 11, 9:00-9:25 a.m. Keynote Speech: Toshiaki Higashihara "Future Achieved by DX of Social Infrastructure – Sustainable Society and Creative Consumer”
- October 12, 9:30-10:00 a.m. Highlight Session "Towards Becoming a Global DX Partner – Hitachi’s Acceleration of Global Lumada Business”
- October 12, 1:30-1:50 p.m. Seminar "How to Combine Knowledge and Ideas by Lumada”
Hitachi Social Innovation Forum 2021 JAPAN Official Site: https://www.service.event.hitachi/en/
About GlobalLogic
GlobalLogic (www.globallogic.com ) is a leader in digital product engineering. We help brands across the globe design and build innovative products, platforms, and digital experiences for the modern world. By integrating experience design, complex engineering, and data expertise -- we help our clients imagine what’s possible and accelerate their transition into tomorrow’s digital businesses. Headquartered in Silicon Valley, GlobalLogic operates design studios and engineering centers around the world, extending our deep expertise to customers in the communications, financial services, automotive, healthcare and life sciences, technology, media and entertainment, manufacturing, and semiconductor industries. GlobalLogic is a Hitachi Group Company.
About Lumada Innovation Hub Tokyo
Lumada Innovation Hub Tokyo is a place where knowledge and ideas are crossed to stimulate innovation. It offers workshops and idea generation with digital human resources such as Design Thinkers and Data Scientists who are familiar with the Japanese market, as well as agile development services that utilize the Digital Transformation experience of the Lumada business.
https://www.hitachi.com/products/it/lumada/global/en/innovation_hub/index.html
About Hitachi, Ltd.
Hitachi, Ltd. (TSE: 6501), headquartered in Tokyo, Japan, is contributed to a sustainable society with a higher quality of life by driving innovation through data and technology as the Social Innovation Business. Hitachi is focused on strengthening its contribution to the Environment, the Resilience of business and social infrastructure as well as comprehensive programs to enhance Security & Safety. Hitachi resolves the issues faced by customers and society across six domains: IT, Energy, Mobility, Industry, Smart Life and Automotive Systems through its proprietary Lumada solutions. The company’s consolidated revenues for fiscal year 2020 (ended March 31, 2021) totaled 8,729.1 billion yen ($78.6 billion), with 871 consolidated subsidiaries and approximately 350,000 employees worldwide. For more information on Hitachi, please visit the company's website at https://www.hitachi.com .
*1 - July 14, 2021 News Release "Hitachi Completes Acquisition of GlobalLogic” https://www.hitachi.com/New/cnews/month/2021/07/f_210714.pdf
*2 - March 22, 2021 News Release " Hitachi Establishes Lumada Innovation Hub Tokyo to Accelerate the Lumada Movement Through New Collaborative Creation With a View to the Post-COVID-19 World” https://www.hitachi.com/New/cnews/month/2021/03/210322a.html
*3 - Design Thinker: Digital human resources who can discover essential corporate issues and propose DX by utilizing design thinking.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210927005848/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom